ATE535602T1 - Modifiziertes insulin mit reduzierter immunogenität - Google Patents

Modifiziertes insulin mit reduzierter immunogenität

Info

Publication number: ATE535602T1
Authority: AT; Austria
Prior art keywords: reduced immunogenicity; modified insulin; insulin; modified; immunogenicity
Prior art date: 2001-01-25

Application number

AT02736480T

Other languages

English (en)

Inventor

Pradip Mukerji

Yung-Sheng Huang

Tapas Das

Jennifer Thurmond

Suzette Pereira

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-25

Filing date

2002-01-24

Publication date

2011-12-15

2002-01-24 Application filed by Abbott Lab filed Critical Abbott Lab

2002-01-24 Priority claimed from PCT/US2002/001924 external-priority patent/WO2002081668A2/en

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535602T1 publication Critical patent/ATE535602T1/de

Links

230000005847 immunogenicity Effects 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Nutrition Science (AREA)
Neurosurgery (AREA)

AT02736480T 2001-01-25 2002-01-24 Modifiziertes insulin mit reduzierter immunogenität ATE535602T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/769,863 US6635451B2 (en)	2001-01-25	2001-01-25	Desaturase genes and uses thereof
US10/054,534 US7067285B2 (en)	2001-01-25	2002-01-22	Desaturase genes and uses thereof
PCT/US2002/001924 WO2002081668A2 (en)	2001-01-25	2002-01-24	Desaturase genes and uses thereof

Publications (1)

Publication Number	Publication Date
ATE535602T1 true ATE535602T1 (de)	2011-12-15

Family

ID=27735000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02736480T ATE535602T1 (de)	2001-01-25	2002-01-24	Modifiziertes insulin mit reduzierter immunogenität

Country Status (8)

Country	Link
US (6)	US6635451B2 (de)
EP (2)	EP2325300B1 (de)
JP (3)	JP4347397B2 (de)
AR (1)	AR035534A1 (de)
AT (1)	ATE535602T1 (de)
CA (2)	CA2698579C (de)
ES (1)	ES2377198T3 (de)
PT (1)	PT1392823E (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6635451B2 (en) *	2001-01-25	2003-10-21	Abbott Laboratories	Desaturase genes and uses thereof
US20050089879A1 (en) *	2001-07-31	2005-04-28	Ivo Feussner	Method for producing arachidonic acid in transgenic organisms
DE10219203A1 (de) *	2002-04-29	2003-11-13	Basf Plant Science Gmbh	Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen
EP1619960A4 (de) *	2003-03-07	2009-03-18	Advanced Bionutrition Corp	Futtermittelformulierung für land- und wasserbewohner
PL1656449T3 (pl) *	2003-08-21	2009-08-31	Monsanto Technology Llc	Desaturazy kwasów tłuszczowych z Primula
CA2562548C (en)	2004-04-16	2019-08-20	Monsanto Technology Llc	Expression of fatty acid desaturases in corn
ES2529572T3 (es)	2004-04-22	2015-02-23	Commonwealth Scientific And Industrial Research Organisation	Síntesis de ácidos grasos poliinsaturados de cadena larga por células recombinantes
AU2011232757B2 (en) *	2004-04-22	2013-10-03	Commonwealth Scientific And Industrial Research Organisation	Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
EP2363492A3 (de)	2004-04-22	2012-03-14	Commonwealth Scientific and Industrial Research Organisation	Synthese von langkettigen polyungesättigten Fettsäuren durch rekombinante Zellen
US7364883B2 (en) *	2004-05-07	2008-04-29	Yeastern Biotech Co., Ltd.	Process for producing poly-unsaturated fatty acids by oleaginous yeasts
BRPI0511236A (pt) *	2004-06-04	2007-11-27	Fluxome Sciences As	método para a produção de ácidos graxos poliinsaturados com quatro ou mais ligações duplas, saccharomyces cerevisiae geneticamente modificado que tem capacidade de produzir ácidos graxos poliinsaturados com quatro ou mais ligações duplas quando desenvolvido em um substrato que não de ácido graxo, composição, uso da composição e uso de um saccharomyces cervisiae geneticamente modificado
US8685679B2 (en) *	2004-11-04	2014-04-01	E I Du Pont De Nemours And Company	Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US7550286B2 (en) *	2004-11-04	2009-06-23	E. I. Du Pont De Nemours And Company	Docosahexaenoic acid producing strains of Yarrowia lipolytica
JP2008532553A (ja) *	2005-03-16	2008-08-21	メタボリックス，インコーポレイテッド	生合成経路の化学的に誘導可能な発現
EP1885862B1 (de)	2005-05-23	2015-07-29	Arcadia Biosciences Inc.	Florsafran mit erhöhter gamma-linolensäure
EP3467096B1 (de)	2005-06-07	2022-01-12	DSM Nutritional Products AG	Eukaryotische mikroorganismen zur herstellung von lipiden und antioxidantien
EP1991047B1 (de)	2006-03-01	2012-09-26	Pioneer Hi-Bred International Inc.	Zusammensetzung in zusammenhang mit dem quantitative trait locus 6 (qtl6) in mais und anwendungsverfahren dafür
US7465793B2 (en)	2006-04-20	2008-12-16	E.I. Du Pont De Nemours And Company	Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids
ES2572833T3 (es) *	2006-08-01	2016-06-02	Dsm Nutritional Products Ag	Proceso de producción de aceite microbiano que contiene ácidos grasos poliinsaturados
US8816106B2 (en)	2006-08-29	2014-08-26	Commonwealth Scientific And Industrial Research Organisation	Synthesis of fatty acids
US7556949B2 (en) *	2006-10-30	2009-07-07	E.I. Du Pont De Nemours And Company	Δ17 desaturase and its use in making polyunsaturated fatty acids
US7943365B2 (en)	2007-05-03	2011-05-17	E.I. Du Pont De Nemours And Company	Δ-5 desaturases and their use in making polyunsaturated fatty acids
US8765422B2 (en) *	2007-07-13	2014-07-01	Dsm Nutritional Products Ag	D4 desaturases and D5 elongases
AU2009276506A1 (en) *	2008-08-01	2010-02-04	E. I. Du Pont De Nemours And Company	Delta6 desaturases and their use in making polyunsaturated fatty acids
CN113957054B (zh)	2008-11-18	2024-07-16	联邦科学技术研究组织	产生ω-3脂肪酸的酶和方法
US8916154B2 (en) *	2009-04-27	2014-12-23	Abbott Laboratories	Antibodies against delta-5 desaturase and uses thereof
US8183227B1 (en)	2011-07-07	2012-05-22	Chemo S. A. France	Compositions, kits and methods for nutrition supplementation
US8168611B1 (en)	2011-09-29	2012-05-01	Chemo S.A. France	Compositions, kits and methods for nutrition supplementation
SG10201810439SA (en)	2012-06-15	2018-12-28	Commw Scient Ind Res Org	Production of long chain polyunsaturated fatty acids in plant cells
US9873880B2 (en)	2013-03-13	2018-01-23	Dsm Nutritional Products Ag	Engineering microorganisms
CA2933909C (en)	2013-12-18	2024-07-02	Commonwealth Scientific And Industrial Research Organisation	Lipid comprising long chain polyunsaturated fatty acids
US10473585B2 (en) *	2014-06-16	2019-11-12	Murphy Brown, Llc	Method and system for measuring a physical parameter of a particulate material
EP3160482A4 (de)	2014-06-27	2018-02-14	Commonwealth Scientific and Industrial Research Organisation	Lipid mit docosapentensäure
CN112741154A (zh) *	2019-10-30	2021-05-04	东北农业大学	一种早产儿配方液态乳及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1982001011A1 (en)	1980-09-24	1982-04-01	Corp Cetus	Diagnostic method and probe
US4582788A (en)	1982-01-22	1986-04-15	Cetus Corporation	HLA typing method and cDNA probes used therein
EP0084796B1 (de)	1982-01-22	1990-05-02	Cetus Corporation	Verfahren zur Charakterisierung von HLA und die darin benutzten cDNS-Testmittel
US4683194A (en)	1984-05-29	1987-07-28	Cetus Corporation	Method for detection of polymorphic restriction sites and nucleic acid sequences
US4945050A (en)	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
US5420034A (en)	1986-07-31	1995-05-30	Calgene, Inc.	Seed-specific transcriptional regulation
US4943674A (en)	1987-05-26	1990-07-24	Calgene, Inc.	Fruit specific transcriptional factors
GB8507058D0 (en)	1985-03-19	1985-04-24	Efamol Ltd	Pharmaceutical & dietary compositions
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
GB8524276D0 (en)	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
GB8524275D0 (en)	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
CA1284931C (en)	1986-03-13	1991-06-18	Henry A. Erlich	Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5107065A (en)	1986-03-28	1992-04-21	Calgene, Inc.	Anti-sense regulation of gene expression in plant cells
US5188958A (en)	1986-05-29	1993-02-23	Calgene, Inc.	Transformation and foreign gene expression in brassica species
CA1338457C (en)	1986-08-22	1996-07-16	Henry A. Erlich	Purified thermostable enzyme
US5004863B2 (en)	1986-12-03	2000-10-17	Agracetus	Genetic engineering of cotton plants and lines
US5416011A (en)	1988-07-22	1995-05-16	Monsanto Company	Method for soybean transformation and regeneration
US5130242A (en)	1988-09-07	1992-07-14	Phycotech, Inc.	Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
IE63225B1 (en)	1988-09-13	1995-04-05	Efamol Holdings	Use of fatty acids in the treatment of myalgic encephalomyelitis
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5106739A (en)	1989-04-18	1992-04-21	Calgene, Inc.	CaMv 355 enhanced mannopine synthase promoter and method for using same
US5196198A (en)	1989-06-02	1993-03-23	Abbott Laboratories	Parenteral nutrition product
US5175095A (en)	1989-07-19	1992-12-29	Calgene, Inc.	Ovary-tissue transcriptional factors
DE69103753T3 (de)	1990-05-25	2008-01-24	E.I. Dupont De Nemours And Co., Wilmington	Nukleotidsequenz des gens für stearoyl-acp-desaturase aus soja.
US5518908A (en)	1991-09-23	1996-05-21	Monsanto Company	Method of controlling insects
PH31293A (en)	1991-10-10	1998-07-06	Rhone Poulenc Agrochimie	Production of y-linolenic acid by a delta6-desaturage.
DK0616644T3 (da)	1991-12-04	2003-10-27	Du Pont	Fedtsyredesaturase-gener fra planter
US5912120A (en)	1992-04-09	1999-06-15	The United States Of America As Represented By The Department Of Health And Human Services,	Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
DE69333025T2 (de)	1992-11-17	2004-04-29	E.I. Du Pont De Nemours And Co., Wilmington	Für mikrosom delta 12 fettsäuredesaturase kodierende gene und verwandte enzyme von pflanzen
ES2148323T3 (es)	1993-02-26	2000-10-16	Calgene Llc	Sistema de expresion de un gen a base de geminivirus.
JPH07228888A (ja)	1994-02-17	1995-08-29	Shimadzu Corp	高度不飽和脂肪酸の精製方法
US5750176A (en)	1994-03-09	1998-05-12	Abbott Laboratories	Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
NZ281041A (en)	1994-03-09	1998-04-27	Abbott Lab	Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
NZ279676A (en)	1994-03-09	1998-04-27	Abbott Lab	Humanized milk produced by non-human transgenic mammal transformed with a heterologous gene coding for human enzyme producing human oligosaccharides and glycoconjugates
US5427857A (en) *	1994-06-28	1995-06-27	E. I. Du Pont De Nemours And Company	Cathodic electrocoating compositions containing branched epoxy amine resins
US5654402A (en)	1994-10-26	1997-08-05	Michigan State University	Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
US5631152A (en)	1994-10-26	1997-05-20	Monsanto Company	Rapid and efficient regeneration of transgenic plants
JPH0913077A (ja)	1995-07-04	1997-01-14	Nisshin Oil Mills Ltd:The	臓器蓄積性の高い油脂
HUP0001517A3 (en) *	1997-04-11	2002-04-29	Calgene Llc Davis	Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
US5972664A (en)	1997-04-11	1999-10-26	Abbott Laboratories	Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
WO1999061602A1 (en)	1998-05-29	1999-12-02	Ohio University	Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products
JP2000069987A (ja)	1998-08-28	2000-03-07	Suntory Ltd	アラキドン酸含有脂質並びにジホモ−γ−リノレン酸含有脂質の製造方法
WO2000020603A1 (en)	1998-10-05	2000-04-13	Abbott Laboratories	Altered fatty acid biosynthesis in insect cells using delta five desaturase
EP1035207A1 (de)	1999-03-09	2000-09-13	MultiGene Biotech GmbH	cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
DE50013231D1 (de)	1999-06-07	2006-09-07	Basf Plant Science Gmbh	Delta6-acetylenase und delta6-desaturase aus ceratodon purpureus
ES2399806T3 (es)	2000-09-28	2013-04-03	Bioriginal Food & Science Corp.	Miembro de la familia de desaturasa de ácido graso fad6 y usos del mismo
EP1392823B1 (de)	2001-01-25	2011-11-30	Abbott Laboratories	Modifiziertes insulin mit reduzierter immunogenität
US6635451B2 (en) *	2001-01-25	2003-10-21	Abbott Laboratories	Desaturase genes and uses thereof

2001
- 2001-01-25 US US09/769,863 patent/US6635451B2/en not_active Expired - Lifetime
2002
- 2002-01-22 US US10/054,534 patent/US7067285B2/en not_active Expired - Lifetime
- 2002-01-24 CA CA2698579A patent/CA2698579C/en not_active Expired - Fee Related
- 2002-01-24 CA CA2699611A patent/CA2699611C/en not_active Expired - Fee Related
- 2002-01-24 AT AT02736480T patent/ATE535602T1/de active
- 2002-01-24 EP EP10184220.1A patent/EP2325300B1/de not_active Expired - Lifetime
- 2002-01-24 ES ES02736480T patent/ES2377198T3/es not_active Expired - Lifetime
- 2002-01-24 PT PT02736480T patent/PT1392823E/pt unknown
- 2002-01-24 EP EP10185334.9A patent/EP2333052B1/de not_active Expired - Lifetime
- 2002-01-25 AR ARP020100289A patent/AR035534A1/es not_active Application Discontinuation
2003
- 2003-05-08 US US10/431,952 patent/US7241619B2/en not_active Expired - Fee Related
2007
- 2007-05-07 US US11/800,631 patent/US20090265798A1/en not_active Abandoned
2008
- 2008-05-13 JP JP2008125523A patent/JP4347397B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152845A patent/JP4347400B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152844A patent/JP4347399B2/ja not_active Expired - Fee Related
2010
- 2010-09-09 US US12/878,788 patent/US8143486B2/en not_active Expired - Fee Related
- 2010-09-09 US US12/878,807 patent/US8143383B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2325300B1 (de)	2013-11-06
JP2008289479A (ja)	2008-12-04
EP2325300A1 (de)	2011-05-25
US8143383B2 (en)	2012-03-27
EP2333052B1 (de)	2013-10-09
JP4347397B2 (ja)	2009-10-21
US20110003360A1 (en)	2011-01-06
ES2377198T3 (es)	2012-03-23
US20090265798A1 (en)	2009-10-22
JP4347400B2 (ja)	2009-10-21
EP2333052A1 (de)	2011-06-15
JP4347399B2 (ja)	2009-10-21
US20030167525A1 (en)	2003-09-04
AR035534A1 (es)	2004-06-02
US20030157144A1 (en)	2003-08-21
US6635451B2 (en)	2003-10-21
US7241619B2 (en)	2007-07-10
US20030190733A1 (en)	2003-10-09
PT1392823E (pt)	2012-03-08
JP2008289491A (ja)	2008-12-04
US7067285B2 (en)	2006-06-27
CA2699611C (en)	2013-12-10
CA2698579A1 (en)	2002-10-17
CA2698579C (en)	2013-12-10
US20110003351A1 (en)	2011-01-06
JP2008289490A (ja)	2008-12-04
US8143486B2 (en)	2012-03-27
CA2699611A1 (en)	2002-10-17

Publication	Publication Date	Title
ATE535602T1 (de)	2011-12-15	Modifiziertes insulin mit reduzierter immunogenität
NO2024004I1 (no)	2024-01-16	insulin degludec
DK3210637T3 (da)	2021-04-06	Infusionssæt
DK1383560T4 (da)	2023-07-24	Infusionssæt
DE60327864D1 (de)	2009-07-16	Ballondissektor mit kanüle
MXPA03007323A (es)	2003-12-12	Proteinas artificiales con inmunogenicidad reducida.
IL165788A0 (en)	2006-01-15	Acidic insulin preparations with improved stability
DE60227076D1 (de)	2008-07-24	Hämodialysator mit verbesserter dialysatperfusion
DE60212066D1 (de)	2006-07-20	Abgabespritze
EP1310252A4 (de)	2009-06-10	Injektionen
DE60213194D1 (de)	2006-08-31	Haltenadel mit flügel
DE60238111D1 (de)	2010-12-09	Viszeralfettmesser mit tonometer
DE60211606D1 (de)	2006-06-29	Reissverschluss mit Endanschlag
DE60306911D1 (de)	2006-08-31	Spaltoven mit gleichmässiger heizung
DE50209245D1 (de)	2007-02-22	Neuroprotektives medikament
DE60200078D1 (de)	2003-12-11	Infusionsbehälter
PL362375A1 (en)	2004-10-18	Modified leptin with reduced immunogenicity
EP1445094A4 (de)	2006-11-02	Lichtschutzfolie
MXPA03007838A (es)	2003-12-08	Interferon alfa modificado con inmunogenicidad reducida.
DE60143148D1 (de)	2010-11-11	En mit honigwaben
EP1497307A4 (de)	2005-11-30	Impfstoff mit rekombinantem p.falciparum-merozoitprotein-1 42
HUP0401121A3 (en)	2006-01-30	Modified thrombopoietin with reduced immunogenicity
DE10111783B4 (de)	2005-10-20	Einspritzdüse
HUP0303523A3 (en)	2005-12-28	Modified insulin with reduced immunogenicity
DE60223642D1 (de)	2008-01-03	Mikroschalter mit demontierbarem Verbinder